Brands
Bajaj Electricals launches multimedia campaign to promote new range of fans
Mumbai: Bajaj Electricals has launched a new multimedia campaign titled ‘Fan Nahin Fantastic’ to unveil its technologically superior range of fans. The campaign is currently live across TV, print, digital and in-store display.
Through this launch, Bajaj Electricals retains its position as the go-to contemporary fan brand for the modern Indian consumer. The brand’s creative agency McCann Worldgroup India has worked on the films.
By introducing such unique advanced features, the brand has reaffirmed its position as a leading player and consumer’s go-to choice in the fan category. Founded on the pillars of innovation, technology and nuanced understanding of the consumers, Bajaj Electricals continues its journey towards building the future and opening the world to newer possibilities.
The brand’s consumer research highlighted that modern Indian consumers are increasingly looking for new-age features in fans and the top three factors they consider while purchasing a fan are speed of the fan, preference for low noise and aesthetic fans that can uplift the home décor, said the statement.
Keeping this in mind, Bajaj Electricals’ latest offering caters to all these requirements. The range includes the super high-speed 425 RPM fans that offer a high blast of air for quick comfort, silent fans with reduced noise levels and decorative fans in ceiling, tower & pedestal range that are in the premium category. The newly launched models can be purchased from all leading retail outlets and e-commerce websites.
“Over the years we have tried to understand the requirements of the consumer and have added Super High-Speed, Silent and Decorative fans to our existing vast range,” said Bajaj Electricals business head of consumer products Krishna Raman. “The latest campaign ‘Fan Nahin Fantastic’ is an interesting articulation of the changing needs of today’s modern consumer and we hope the new TVC shown in a lighter vein will strike a chord with them. With the latest range, we aim to go beyond the basic requirement of fans as an appliance by enhancing functionality and appearance in a way that enables our fans to seamlessly fit in our consumer’s daily life.”
“We wanted to create a sharp, disruptive, and humorous storytelling that is completely driven by functionality and highlights the product proposition. The new range of Bajaj fans are designed with technological innovation that offer a bouquet of consumer benefits, tailored to the varied demands of the new-age consumers. And our campaign idea ‘Fan Nahin Fantastic’ demonstrates and underlines this unique proposition,” added McCann Worldgroup executive director and head of creative Ashish Chakravarty.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
